Successful treatment of lymphocutaneous sporotrichosis with fosravuconazole
The Journal of Dermatology · 2025-06 · 52 (6)
DOI: 10.1111/1346-8138.17680 ↗Kurz gefasst
Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 28.02.2025. Verfasst von Yumie Tokuhisa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sakurayama Dermatology Clinic, Yamaguchi, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Fosravuconazole is a novel oral antifungal drug developed in Japan that has been used to treat tinea unguium since 2018. It has excellent oral absorbability, and systemic bioavailability has enhanced its efficacy.1 There are no contraindications due to mild CYP450 inhibition, which helps reduce polypharmacy effects. Potassium iodide is the first-line treatment in Japan, while itraconazole is the global standard treatment.2 We report the first case of lymphocutaneous sporotrichosis treated with fosravuconazole, prescribed due to concomitant onychomycosis. A 60-year-old male former office worker with a history of hypertension developed progressive nodular lesions following a scratch from his pet cat 3 months previously. His cat is a healthy cat that never goes outside. Initially misdiagnosed as a bacterial infection, his condition worsened despite antibiotics, with new nodules appearing on the forearm. A physical examination revealed a 25 × 35-mm ulcerated nodule with crusts on the right hand (Figure 1a), two 8-mm subcutaneous masses on the mid-forearm, and a 10 × 8-mm erythematous nodule near the elbow (Figure 1b). The lesions were painless. Although direct microscopic examination of the lesions with KOH was negative, periodic acid-Schiff (PAS) staining of crust smears revealed fungal hyphae with germinated spores. Histopathology revealed granulomatous inflammation with PAS-positive spores in the dermis, confirming lymphocutaneous sporotrichosis (Figure 1c). Plate culture on Sabouraud dextrose agar grew a gray velvety colony with a dark-brown pigmentation on the reverse after 4 weeks at 25°C (Figure 1d). The slide culture showed septate hyphae and hyaline or pigmented conidia grouped in a rosette-like structure at the conidiophore tips (Figure 1e). Antifungal susceptibility testing of the isolate was performed according to the Clinical and Laboratory Standards Institute M38-A2 protocol. The minimum inhibitory concentrations (MICs) for itraconazole, posaconazole, ravuconazole, and terbinafine were 0.125, 0.5, 0.5 and 2 μg/mL, respectively. Both the internal transcribed spacer sequences and calmodulin gene of the isolate showed 100% homology (522/522 and 594/594 bp, respectively), with the Sporothrix globosa strain CBS 292.55T (GenBank accession numbers: KP017086 and KP101476). Oral fosravuconazole (100 mg daily) led to rapid improvement after 2 weeks (Figure 1f). The lesions resolved with scarring and all lesions disappeared within 12 weeks (Figure 1g). There were no adverse effects and no recurrence was observed at the 7-month follow-up (Figure 1h). Fosravuconazole was prescribed for concomitant tinea unguium, but no additional treatment was required due to the rapid resolution of symptoms. The most common cause of sporotrichosis in Japan is Sporothrix globosa.3 In contrast, Sporothrix schenckii is primarily found in tropical and subtropical regions, especially Central and South America, Africa, and parts of Asia.4 Sporothrix brasiliensis, which is highly endemic to Brazil, is associated with zoonotic transmission via cats and is known for its high virulence.4 There have been reports of antifungal resistance in S. brasiliensis, particularly against itraconazole.5 Ravuconazole demonstrates strong antifungal activity against S. brasiliensis and related species, with MICs comparable to those of itraconazole and voriconazole. Its long half-life allows for once-daily dosing, enhancing patient compliance in chronic cases. These characteristics make fosravuconazole a promising option, particularly for treating severe or resistant infections. None declared.
Autor:innen und Institutionen
- Sakurayama Dermatology Clinic, Yamaguchi, Japan.
- Noguchi Dermatology Clinic, Kumamoto, Japan.
- Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, Japan.
- Teikyo University Institute of Medical Mycology, Tokyo, Japan.
ORCID-Profile: Yumie Tokuhisa, Hiromitsu Noguchi, Rui Kano
Zitieren
APA
Tokuhisa, Y., Tokuhisa, Y., Noguchi, H., Hiruma, M., & Kano, R. (2025). Successful treatment of lymphocutaneous sporotrichosis with fosravuconazole. The Journal of Dermatology, 52(6). https://doi.org/10.1111/1346-8138.17680
Vancouver
Tokuhisa Y, Tokuhisa Y, Noguchi H, Hiruma M, Kano R. Successful treatment of lymphocutaneous sporotrichosis with fosravuconazole. The Journal of Dermatology. 2025;52(6). doi:10.1111/1346-8138.17680
BibTeX
@article{Tokuhisa2025,
author = {Tokuhisa, Yumie and Tokuhisa, Yoshihiro and Noguchi, Hiromitsu and Hiruma, Masataro and Kano, Rui},
title = {Successful treatment of lymphocutaneous sporotrichosis with fosravuconazole},
journal = {The Journal of Dermatology},
year = {2025},
volume = {52},
number = {6},
doi = {10.1111/1346-8138.17680}
}
EUVIMED